Key Details
Price
$0.61Annual ROE
-153.37%Beta
0.83Events Calendar
Next earnings date:
Mar 13, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 18, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced today that it will be releasing its financial results for the first quarter of 2024 on Thursday, May 9, 2024 before the market opens.
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023.
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman - Maxim Group Laura Suriel - Alliance Global Partners Operator Good morning.
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. According to a filing from Quoin Pharmaceuticals, the company is enacting an ADS ratio change that will switch its stock from one for 5,000 shares to one for 6,000 shares.
FAQ
- What is the primary business of Quoin Pharmaceuticals?
- What is the ticker symbol for Quoin Pharmaceuticals?
- Does Quoin Pharmaceuticals pay dividends?
- What sector is Quoin Pharmaceuticals in?
- What industry is Quoin Pharmaceuticals in?
- What country is Quoin Pharmaceuticals based in?
- When did Quoin Pharmaceuticals go public?
- Is Quoin Pharmaceuticals in the S&P 500?
- Is Quoin Pharmaceuticals in the NASDAQ 100?
- Is Quoin Pharmaceuticals in the Dow Jones?
- When was Quoin Pharmaceuticals's last earnings report?
- When does Quoin Pharmaceuticals report earnings?
- Should I buy Quoin Pharmaceuticals stock now?